{"acquisitions":[],"changes":[],"country":"FR","description":"Apmonia Therapeutics develops peptide-based immunotherapies that disrupt the tumor micro-environment and stimulate immune response in solid tumors. It serves oncologists and patients with cancers where existing checkpoint inhibitors are ineffective. The TAX2 peptide-driven approach targets thrombospondin pathways that small-molecule and antibody oncology programs have largely left untouched.","domain":"apmoniatherapeutics.com","employees":null,"founded":2017,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":48.693722,"lng":6.18341,"location":"Nancy, France","multiples":[],"name":"APMONIA THERAPEUTICS","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2624400,"connectionsAmong":[],"currency":"EUR","date":"2024-07-15","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"apmoniatherapeutics-com-2024-07-15-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"apmoniatherapeutics-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"apmoniatherapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://apmoniatherapeutics.com"},{"fact":"description","publisher":"apmoniatherapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://apmoniatherapeutics.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":2624400,"traction":[],"updatedAt":"2026-05-08","valuations":[]}